## COO: The Cooper Companies, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.87 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($73.13)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 6
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Norges Bank Invests $35.06 Million in The Cooper Companies, Inc. $COO**
- Source: MarketBeat | 20251208T104621 | Somewhat-Bullish | Relevance: 99%
-  Norges Bank recently acquired a significant stake in The Cooper Companies, Inc. (NASDAQ:COO), purchasing 492,706 shares valued at approximately $35.06 million during the second quarter. This investment makes Norges Bank a substantial shareholder, owning about 0.25% of the company. The article also details other institutional investor activities, analyst ratings, and insider transactions related to Cooper Companies, highlighting a "Moderate Buy" consensus and a $90.31 average target price.

**2. Cooper Companies price target raised to $88 from $72 at Citi**
- Source: TipRanks | 20251208T140823 | Bullish | Relevance: 98%
- Citi has raised its price target for Cooper Companies (COO) to $88 from $72, while maintaining a Neutral rating on the shares. This adjustment follows the company's better-than-expected fiscal Q4 results, which broke a trend of previous misses. The upgrade reflects a positive outlook on Cooper Companies' recent financial performance.

**3. Why Cooper Companies (COO) Is Up 5.2% After Strategic Review, Buyback Completion And 2026 Outlook**
- Source: Simply Wall Street | 20251208T110823 | Somewhat-Bullish | Relevance: 97%
- CooperCompanies' stock (COO) rose 5.2% after reporting Q4 and full-year 2025 results, outlining a strategic review, completing a significant share buyback, and providing a 2026 outlook. The company's revenue increased, but net income and EPS were lower compared to the previous year, prompting an increased focus on portfolio optimization and capital allocation. This strategic review, along with a new share repurchase focus, aims to reinforce capital returns and support the narrative of improving profitability despite challenges in the contact lens market.

**4. Cooper Companies (COO) Valuation: Reassessing Upside After Earnings Beat, Strong 2026 Outlook and Strategic Review**
- Source: Simply Wall Street | 20251209T130758 | Somewhat-Bullish | Relevance: 97%
- Cooper Companies (COO) recently announced an earnings beat, a strong 2026 outlook, and a strategic review, leading to an 11.32% share price recovery over 30 days, despite a substantial 21.38% drop over the last year. The company is currently considered 6% undervalued, trading at $78.04 against a fair value estimate of $83.00, driven by anticipated free cash flow generation and debt reduction. However, a high P/E ratio and pressure in the contact lens and fertility markets pose risks to the recovery.

**5. Why Cooper Companies (COO) Is Up 5.2% After Strategic Review, Buyback Completion And 2026 Outlook**
- Source: Simply Wall Street | 20251208T110821 | Somewhat-Bullish | Relevance: 96%
-  CooperCompanies reported Q4 and full-year 2025 results with increased revenue but lower net income and diluted EPS compared to the prior year. Following a strategic review, the company announced updated 2026 revenue guidance and completed a $1.03 billion share repurchase, with a new $2 billion program. The strategic review and capital returns aim to optimize the portfolio and support profitability amidst fluctuating market conditions and slow contact lens growth.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 10, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-08 | Citigroup | $88 | $72 | +22% |
| 2025-12-08 | Morgan Stanley | $83 | $76 | +9% |
| 2025-12-08 | Goldman Sachs | $71 | $64 | +11% |
| 2025-12-05 | Stifel | $95 | $85 | +12% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-08 | Citigroup | main | Neutral |
| 2025-12-08 | Morgan Stanley | main | Equal-Weight |
| 2025-12-08 | Goldman Sachs | main | Sell |
| 2025-12-05 | Stifel | reit | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 1 ($0.14M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (-1.1%)
- Blackrock Inc.: 7.7% (-0.8%)
- Capital World Invest: 5.3% (+25.7%)
- T. Rowe Price Invest: 4.9% (+33.2%)
- State Street Corpora: 4.3% (-0.9%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 10 raises (avg +14%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 0.87 indicates undervaluation relative to growth. Analyst sentiment positive (10 raises, avg +14%). Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $15.7B |
| Beta | 1.05 |
| 52W Range | $61.78 - $100.47 |
| Short Interest | 3.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.87 |
| Forward P/E | 15.9 |
| Current P/E | 17.4 |
| YoY Growth | 9.5% |
| EPS Direction | STABLE |

### Technicals

MRS_20 improving modestly (+0.6% over 5 days). Below STRENGTH zone by 1.9pp (needs >4.0% for momentum thesis). MRS_5 at 0.2% confirms short-term momentum alignment. AM_20 at 4.3% shows strong absolute momentum above own 20MA. Outperforming sector by 6.7pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). Elevated volume (1.9x 20MA), institutional activity likely.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 2.15% (CS: 73) | Neutral |
| RSI_14 | 60.8 | Neutral |
| MACD Histogram | 0.28 | Bullish |
| vs SMA20 | 1.044x | Above |
| vs SMA50 | 1.083x | Above |
| vs SMA200 | 1.050x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $78.51
- **Stop Loss:** $73.13 (6.9% risk)
- **Target:** $89.27 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 55
- **Position Value:** $4,318.05
- **Portfolio %:** 4.32%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not invertedâ€”indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-03-05 (Est: $1.03)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $1.11 | $1.15 | +3.3% |
| 2025Q3 | $1.07 | $1.10 | +3.0% |
| 2025Q2 | $0.93 | $0.96 | +3.3% |
| 2025Q1 | $0.91 | $0.92 | +0.9% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*